SocialPicks Sentiment:
** v.s.
other stocks
|
This Quarter's Sentiment:
|
|
|
BIIB Analysis & Videos »
BIIB: Bull or Bear?
David Fried's Buyback Premium Portfolio: Mid-Month Update
BIIB
+99.89%
in
543 days
Filed under: Coca-Cola (KO), Newsletters, AutoZone Inc (AZO), H and R Block (HRB), Coca-Cola Enterprises (CCE), Family Dollar Stores (FDO), Stocks to Buy, Stock Picks  Our recommendations for the Buyback Premium Portfolio center on a collection of five stocks that we believe, as a group, will outperform the market this month.
The Buyback Premium Portfolio has beat the S&P 500 by more than 72% since its inception (August 2, 2000)! It is up 54.87% since inception vs. a decline of 17.90% in the S&P 500. For the month of November, the portfolio gained 3.41% vs. a decline of 0.23% in the S&P 500. <><>C...
|
Biogen Idec Looks Bullish on Earnings Guidance
BIIB
+149.87%
in
685 days
Filed under: Earnings Reports, Stocks to Buy  Biogen Idec (BIIB) improved its bullish prospects today as it announced earnings of $1.31 per share -- well above the Wall Street consensus estimate of $1.12 -- and raised its 2010 earnings outlook.
Total revenue for last quarter -- thanks in large part to better-than-expected sales of Biogen's multiple sclerosis drug Avonex -- came in at $1.2 billion, up 11% year over year. Perhaps most exciting, however, was Biogen's announcement that it is raising its guidance for 2010 earnings to $4.70 per share, up from the current consensus of $4.57. <><>Continue r...
|
FDA Calendar Updates: Amgen, Bayer, Biogen, Noveko, Peplin, Transdel
BIIB
|
|
|
+193.28%
in
1062 days
<> Below is a summary of updates to the <font> BioMedReports.com FDA Calendar </font> , which includes a database of 246 entries as of 7/8/09. The calendar was originally created by Mike Havrilla to track companies with pending new drug, biological agent, or medical device new product decisions at the FDA. With the launch of <font> BioMedReports.com </font> , the FDA Calendar has expanded to include the following categories: pending new submissions to the FDA (e.g. NDA, BLA, 510k, PMA, sNDA, sBLA filings), pending complete response letter (CRL) re-submissions to the FDA, and pending...
|
FDA Decision Calendar: Pain Drug Delays Likely
BIIB
|
|
|
-12.22%
in
148 days
(closed on 07/08/09)
FDA Decision Calendar: Pain Drug Delays Likely By Mike Havrilla on 2/9/09 ETF Innovators The tables at my website link below include an updated calendar of 86 expected FDA new product decisions and 89 pending clinical trial result estimates + pending FDA re-submissions or new submissions for regulatory approval. Click here for a link to my previous calendars. New FDA Decision Calendar Entries: <> 1.) Biogen Idec (BIIB) and Genentech (DNA) have a PDUFA...
|
Drug and health care stocks: The right prescription for 2009
BIIB
+178.94%
in
1246 days
Filed under: Pfizer (PFE), Newsletters, Johnson and Johnson (JNJ), Bristol-Myers Squibb (BMY), Stocks to Buy, Best Stocks for 2009  Health care has long been considered a recession-resistant business. Given the current economic challenges, it's little surprise that in our survey of favorite stocks for the coming year, a number of leading advisors turned to this classic defensive sector.
<>In this year's Top Stock Picks from 75 advisors report, we found an intriguing group of medical-related stocks, from speculation in emerging biotech to well-established pharmaceutical firms, and from medical pr...
|
Biotech no longer a safe haven: Elan (ELN) falls on hard times
BIIB
-183.97%
in
1269 days
Filed under: Pfizer (PFE), Newsletters, Merck and Co (MRK), Stocks to Sell  It's been a tough year for many industries -- there's no denying it. Retailers of all stripes, oil companies, construction firms, financials, basic materials companies -- you name it, it's down.
So, are there any safe havens? Historically, in times of economic uncertainty the pharmaceutical industry, along with consumer staples, is often the "go to" place where, at a minimum, you can count on a nice dividend yield to shield your portfolio from gigantic losses. Not anymore. <>In this downturn even stalwarts such as Merck (...
|
Biogen Reports Another PML Case in Tysabri Patient
BIIB
|
|
|
+29.15%
in
102 days
(closed on 02/10/09)
<> 
After the market close, Biogen (BIIB) filed an 8-K with the SEC reporting a new case of the potentially fatal brain disease known as PML or progressive multifocal leukoencephalopathy in a patient receiving their multiple sclerosis [MS] drug Tysabri, adding to the two new cases which were reported previously in July. Biogen is currently trading down by about 15% after hours while marketing partner Elan (ELN) is down by about 25% as of 5:15 PM. The news adds more uncertainty to Tysabri, which was removed from th...
|
Biogen Reports Another PML Case in Tysabri Patient
BIIB
|
|
|
+0.00%
in
3 hours
(closed on 10/30/08)
<>
After the market close, Biogen (BIIB) filed an 8-K with the SEC reporting a new case of the potentially fatal brain disease known as PML or progressive multifocal leukoencephalopathy in a patient receiving their multiple sclerosis [MS] drug Tysabri, adding to the two new cases which were reported previously in July. Biogen is currently trading down by about 15% after hours while marketing partner Elan (ELN) is down by about 25% as of 5:15 PM. The news adds more uncertainty to Tysabri, which was removed from th...
|
Biotech Blues: Four Stocks on Sale with Hope
BIIB
|
|
|
-3.42%
in
4 days
(closed on 10/29/08)
<> The following group of biotech companies have market caps of at least $300M with a one year stock price change that is below the iShares Nasdaq Biotech ETF (IBB) loss of 21.8% (Source: Google Finance, 10/25/08) with potential upside catalysts over the next year.
Alnylam Pharma (ALNY): $872M, -31.6%
Biogen Idec (BIIB): $12B, -48.4%
BioMarin Pharma (BMRN): $1.7B, -33%
Momenta Pharma (MNTA): $348M, -23.4%
Momenta and Novartis (NVS) expect to launch a generic version (M-Enoxaparin) of the injectable...
|
Who's Next in the Biotech Buyout Frenzy?
BIIB
|
|
|
-6.30%
in
12 days
(closed on 10/25/08)
<> The biotech industry is rapidly consolidating as big pharma companies put their cash stash to use in deals ranging from well-known large caps all the way down to unknown micro-caps in an effort to bolster their range of marketed products, late stage pipeline candidates, and drug discovery technology platforms.
Genentech (DNA) has rejected Roche's (RHHBY) $89 bid to acquire the remaining 44% of DNA it does not already own as insufficient. I think DNA could easily get $100 per share based on Eli Lilly's (LLY) $70 buyout of ImClo...
|
An Even Pfatter Yield at Pfizer
BIIB
|
|
|
+0.00%
in
1 hours
(closed on 10/13/08)
<> As I have written previously on Pfizer (PFE), I continue to recommend shares of the Company as a turnaround play around the $15 per share level, which equates to an even fatter dividend yield of 8.5% since I first wrote about the stock in July trading two bucks higher before the market meltdown occurred. Despite significant patent challenges to Lipitor and other products in Pfizer’s portfolio over the next few years, the Company’s strong balance sheet, marketing muscle, and ability to bolster its pipeline through targeted acquisitions should < />< />< />< />< />< />...
|
Clarity on Tysabri Makes Elan and Biogen a Buy
BIIB
|
|
|
+172.34%
in
1366 days
<> The FDA has published a table with the names of products and potential signals of serious risks and/or new safety information identified for these products during 1Q08 in the AERS database. The FDA notes that patients should not stop taking these medications and should consult their prescriber with any questions as the agency will investigate each of the claims further before taking action or issuing more definitive statements on the reported concerns. Some highlights from this table of produ...
|
Clarity on Tysabri Makes Elan and Biogen a Buy
BIIB
|
|
|
-9.49%
in
35 days
(closed on 10/11/08)
<> The FDA has published a table with the names of products and potential signals of serious risks and/or new safety information identified for these products during 1Q08 in the AERS database. The FDA notes that patients should not stop taking these medications and should consult their prescriber with any questions as the agency will investigate each of the claims further before taking action or issuing more definitive statements on the reported concerns. Some highlights from this table of produ...
|
Biogen-Idec, Elan: Panic Selling Creates Interesting Opportunity
BIIB
+161.11%
in
1392 days
In July, Biogen-Idec (BIIB) and Elan (ELN), who co-market the multiple sclerosis drug Tysabri, announced two new cases of PML, a potentially deadly side effect. The stocks sold-off almost entirely. Biogen-Idec lost about 30% of its market share while Elan has lost over two thirds of its value.
 I had previously recommended shares of Biogen-Idec right after the buyout rumors vanished and the stock was trading around 54. I had based that recommendation on the potential success of Tysabri.
|
People Bullish on BIIB
People Bearish on BIIB
|
ROCK-STAR INVESTORS
|
|
POPULAR STOCKS
|
|
TODAY'S HEADLINES
|
|
TODAY'S TOP PICKS
|
|
|
| StreetInsider.com on BIIB |
More Resources
|
About Biogen Idec Inc
- Answers.com
